Condition
Renal Protection
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 4 (1)
Trial Status
Unknown2
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06521697Phase 4Not Yet Recruiting
Effects of Minimal-Flow Sevoflurane and Multimodal Analgesia in Head and Neck Cancer Surgery
NCT05946122Phase 1UnknownPrimary
Effect of Atorvastatin as a Renal Protection in Patients With Systemic Inflammatory Response Syndrome Using Renal Arterial Resistive Index
NCT00497666Unknown
Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study
Showing all 3 trials